Enhancing the expression and function of an EBV-TCR on engineered T cells by combining Sc-TCR design with CRISPR editing to prevent mispairing

Cell Mol Immunol. 2020 Dec;17(12):1275-1277. doi: 10.1038/s41423-020-0396-9. Epub 2020 Mar 17.

Shao-An Xue^#^{1

2}, Yuan Chen^#^{3

4}, Ralf-Holger Voss⁵, Virad Kisan⁴, Bo Wang³, Ke-Ke Chen³, Feng-Qin He³, Xiao-Xia Cheng³, Laura Scolamiero⁴, Angelika Holler⁴, Liquan Gao⁴, Emma Morris⁴, Hans J Stauss⁶

¹ Key Laboratory of Natural Product Development & Anticancer Innovative Drug Research in Qinling, Xi'An. Xi'An University, Xi'An, 710065, P. R. China. shao-an.xue@ucl.ac.uk.
² Institute of Immunity & Transplantation, University College London Medical School, Royal Free Hospital, Rowland Hill Street, London, NW3 2PF, UK. shao-an.xue@ucl.ac.uk.
³ Key Laboratory of Natural Product Development & Anticancer Innovative Drug Research in Qinling, Xi'An. Xi'An University, Xi'An, 710065, P. R. China.
⁴ Institute of Immunity & Transplantation, University College London Medical School, Royal Free Hospital, Rowland Hill Street, London, NW3 2PF, UK.
⁵ Research Center for Immunotherapy (FZI), University Medical Center of Johannes Gutenberg University, Mainz, Germany.
⁶ Institute of Immunity & Transplantation, University College London Medical School, Royal Free Hospital, Rowland Hill Street, London, NW3 2PF, UK. h.stauss@ucl.ac.uk.

^# Contributed equally.

No abstract available

Publication types